![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Allergan Aesthetics looks to further develop the Hybrid Injectables category by introducing its first dual-effect product, which combines the two active ingredients - hyaluronic acid, a well-known ingredient found in facial fillers and calcium hydroxyapatite in one injection.
Lead Product(s): Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area: Dermatology Product Name: HArmonyCa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.
Lead Product(s): Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area: Dermatology Product Name: HArmonyCa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Innovative Luminera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 07, 2020